NovaRock Biotherapeutics to Present at the 10th Annual Immuno-Oncology Summit 2022

Ewing, NJ, October 13, 2022 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody therapies for cancer and inflammatory diseases announced today that Dr. Raymond Yu, Director of Preclinical, will present at the 10^th Annual Immuno-Oncology Summit 2022 held in Boston, Massachusetts and on October 12-14, 2022.  Dr. Yu’s oral presentation highlights our highly potent and safe CD137 Bispecific Antibody Platform for the Development of Solid Tumor Therapeutics.

Session Category: NOVEL STRUCTURES AND FORMATS
Date:  Thursday, October 13, 2022, at 11:30EST

Abstract: First-generation CD137 agonists reached limited clinical outcomes due to hepatotoxicity and/or poor efficacy. With a “fit-for-purpose” design, NovaRock developed a CD137 bispecific platform to activate the co-stimulatory pathway through TAA-mediated receptor clustering. These bispecific antibodies reprogram the tumor microenvironment to elicit potent anti-tumor effects without detectable toxicity and long-lasting immunological memory. Additionally, these antibodies have been optimized to facilitate development and manufacturing. The lead antibody NBL-028 is currently in the IND-enabling stage.